Lena A. Basile, Tujunga US
Lena A. Basile, Tujunga, CA US
Patent application number | Description | Published |
---|---|---|
20120189577 | USE OF IL-12 TO INCREASE SURVIVAL FOLLOWING ACUTE EXPOSURE TO IONIZING RADIATION - The present invention is directed to methods of increasing survival following exposure to non-therapeutic radiation comprising administration of IL-12. | 07-26-2012 |
20130012452 | METHOD FOR TREATING BRAIN CANCER USING A NOVEL TUMOR SUPPRESSOR GENE AND SECRETED FACTOR - The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers. | 01-10-2013 |
20130129674 | IL-12 FORMULATIONS FOR ENHANCING HEMATOPOIESIS - Provided are formulations for proteins to be injected into mammals. Specifically, formulations for recombinant IL-12 in mice and primates. | 05-23-2013 |
20130259828 | USES OF IL-12 AND THE IL-12 RECEPTOR POSITIVE CELL IN TISSUE REPAIR AND REGENERATION - The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells. | 10-03-2013 |
20140178335 | USE OF IL-12 TO GENERATE ENDOGENOUS ERYTHROPOIETIN - The present invention relates to the use of exogenous interleukin-12 (IL-12) for increasing endogenous production of erythropoietin. | 06-26-2014 |
20140342995 | METHOD FOR TREATING BRAIN CANCER USING A NOVEL TUMOR SUPPRESSOR GENE AND SECRETED FACTOR - The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers. | 11-20-2014 |
20140369958 | IL-12 FOR RADIATION PROTECTION AND RADIATION-INDUCED TOXICITY MITIGATION - Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising inter-leukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma. | 12-18-2014 |
20150110739 | USES OF IL-12 AND THE IL-12 RECEPTOR POSITIVE CELL IN TISSUE REPAIR AND REGENERATION - The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells. | 04-23-2015 |